1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6667D79A07965DB470025860100314E04
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-use-of-digital-technologies-within-medical-affairs-digital-landscape-activities?opendocument
18
19opendocument
203.237.66.86
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Digital Technology Cross-Functional Digital Transformation

Best Practices in the Use of Digital Technologies within Medical Affairs: Digital Landscape and Activities in Medical Affairs

ID: 5644


Features:

11 Info Graphics

25 Data Graphics

600+ Metrics


Pages/Slides: 45


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
on-members: Click here to review a complimentary excerpt from “Best Practices in the use of Digital Technologies within Medical Affairs: Digital Landscape and Activities in Medical Affairs”

STUDY OVERVIEW

Biopharma organizations are increasingly turning to digital tools to shape Medical Affairs’ interactions with key stakeholders. As the medical function shifts more of its activities to digital, it needs to ensure it is prioritizing its stakeholder digital efforts and creating a roadmap for executing an effective digital strategy.

Best Practices, LLC conducted this benchmarking research to probe the use of digital technologies within Medical Affairs. The study provides benchmarks around the digital services and capabilities in Medical Affairs.

Medical leaders can use this study to better understand the critical success factors for digital effectiveness within Medical Affairs.

Insights in this study are further presented into three different segments: Digital Leaders; Digital Majority; and Digital Laggards.

KEY TOPICS

  • Digital Initiative in Medical Affairs
  • Digital Services to Medical Affairs Groups
  • Digital Capabilities in Medical Affairs

KEY METRICS

I. Digital Initiative Overview and Key Findings

  • Critical success factors of digital engagement programs in Medical Affairs – Total benchmark class
  • Critical success factors of digital engagement programs in Medical Affairs – Digital leaders vs. digital majority vs. digital laggards
  • Why do the leaders succeed while others struggle?
  • Overview of digital findings
  • Detailed digital findings
  • Top digital activities of the future
  • Best digital channels for serving key external stakeholders
  • Benefits of using digital channels
II. Digital Landscape in Medical Affairs
  • Groups served by Medical Affairs through digital channels – Total benchmark class
  • Importance vs. effectiveness matrix of various groups to Medical Affairs’ digital initiative plans – Total benchmark class
  • Groups served by Medical Affairs through digital channels – Digital leaders vs. digital majority vs. digital laggards
  • Importance vs. effectiveness matrix of various groups to Medical Affairs’ digital initiative plans – Digital leaders, Digital Majority and Digital Laggards


SAMPLE KEY FINDINGS
  • Virtual advisory boards and peer-to-peer interactions were the only e-medical channels that a majority said were “very effective” in increasing medical’s engagement with external stakeholders.

METHODOLOGY

Best Practices, LLC engaged 74 executives from 53 leading life sciences companies in this research through a benchmarking survey instrument and interviews. The study insights are mostly from directors and higher management executives, representing nearly 80% of the participants. Insights in this research are presented into three different segments to provide deeper insights: Digital Leaders (16 respondents); Digital Majority (38 respondents); and Digital Laggards (20 respondents).

Industries Profiled:
Biotech; Medical Device; Pharmaceutical; Biopharmaceutical; Diagnostic; Health Care; Chemical; Manufacturing; Communications; Clinical Research; Laboratories; Science; Consulting


Companies Profiled:
Aeglea BioTherapeutics; Alcon; Alexion Pharmaceuticals; Alkermes; Alnylam Pharmaceuticals; Astellas; AstraZeneca; BioDelivery Sciences International; Inc.; Biodesix; bioMerieux; Boehringer Ingelheim; Eisai; Eli Lilly and Company; EMD Serono; Exelixis ; GE Healthcare; Genentech; GRAIL; Grifols; GlaxoSmithKline ; Ipsen; Janssen; Jazz Pharmaceuticals; Julphar; Kedrion Biopharma; Lexicon Pharmaceuticals; Lundbeck; Mallinckrodt; Merck; MyoKardia; Nabriva Therapeutics; NexGen Healthcare Communications; Novartis; Novo Nordisk; Pfizer; Radius Health; Reata Pharmaceuticals; Roche; Sage Therapeutics; Sandoz; Sanofi; Sanofi Genzyme; Santen; Springworks Therapeutics; Sunovion; Takeda Pharmaceuticals; Terumo Corporation; Teva Pharmaceutical Industries Ltd; TG Therapeutics; Thermo Fisher Scientific; UCB Pharma; Vertex Pharmaceuticals; Vynamic

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.